Shire PLC (SHPG)

193.86
0.96 0.49
NASDAQ : Health Care
Prev Close 194.82
Open 195.03
Day Low/High 193.23 / 195.27
52 Wk Low/High 147.60 / 270.63
Volume 1.43M
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 300.07M
Market Cap 58.46B
EPS 6.60
P/E Ratio 52.94
Div & Yield 0.28 (0.10%)

Latest News

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

- Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

9 Stocks Smart Investors Put Their Money in Last Quarter

9 Stocks Smart Investors Put Their Money in Last Quarter

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

Utilities Need to Get Their Act Together

If they're underperforming, they're typically a precursor to a market correction.

Radius Health, Subject of Takeover Talk, Rises Again

Radius Health, Subject of Takeover Talk, Rises Again

The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI [von Willebrand factor (Recombinant)] is a significant advancement for the treatment of adults with von Willebrand disease (VWD)

Analysts' Actions -- Tableau, Garmin, Pioneer, Shire and More

Analysts' Actions -- Tableau, Garmin, Pioneer, Shire and More

Here are Thursday's top research calls, including downgrades for Tableau Data, Garmin and Pioneer Natural Resources, and an upgrade for Chegg.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMED, CGNX, CHGG, ENSG, FOMX, GATX, MIC, RPAI, SBRA, TDC, TSRI, TX, TZOO, WNRL Downgrades: AMIC, FE, SHPG, SOHU, TCBI Initiations: GPP Read on to get TheStreet Quant Ratings' detailed report:

Today's Unusual Social Activity Stock: Shire (SHPG)

Today's Unusual Social Activity Stock: Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as an unusual social activity candidate

Shire’s Share Surge on Strong Second-Quarter Results

Shire’s Share Surge on Strong Second-Quarter Results

The Ireland-based biopharma company lifts its forecast for Baxalta-related cost savings.

What to Expect When Shire (SHPG) Reports Q2 Earnings Tomorrow

What to Expect When Shire (SHPG) Reports Q2 Earnings Tomorrow

Shire (SHPG) is slated to report fiscal 2016 second quarter earnings and revenue before tomorrow's market open.

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

New system reduces number of steps in the treatment process for hemophilia A patients on ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

3 Stocks Pushing The Health Care Sector Downward

3 Stocks Pushing The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

Shire committed to advancing treatment and raising standards of care for hemophilia patients around the world